Clinical Neuropharmacology

Skip Navigation LinksHome > August 1990 - Volume 13 - Issue 4 > Modulatory Role for CCK-B Antagonists in Parkinson's Disease...
Clinical Neuropharmacology:
Original Contributions: PDF Only

Modulatory Role for CCK-B Antagonists in Parkinson's Disease.

Boyce, S.; Rupniak, N. M. J.; Tye, S.; Steventon, M. J.; Iversen, S. D.

Collapse Box


Summary: We examined the ability of selective CCK-A and CCK-B receptor antagonists to induce or modulate the locomotor stimulant effects of dopamine agonists in MFTP-treated squirrel monkeys. Administration of 1-100 [mu]g/kg i.p. of either the selective CCK-A receptor antagonist devazepide (MK-329) or the CCK-B receptor antagonist L-365,260 alone failed to stimulate a locomotor response in parkinsonian monkeys. In contrast, treatment with L-365,260 caused a 50-60% potentiation of the locomotor stimulatory effects of L-DOPA or (+)-PHNO. No such modulatory effects were observed following pretreatment with devazepide. We suggest that CCK-B receptor antagonists may be useful adjuncts to existing dopamine replacement therapy for improved management of Parkinson's disease.

(C) Williams & Wilkins 1990. All Rights Reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.